MedTrace Logo

Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112

NCT04375865 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-06

No results posted yet for this study

Summary

A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between AD-2111 and AD-2112

Conditions

Interventions

DRUG

AD-2111

celecoxib 200mg

DRUG

AD-2112

Tramadol 150mg

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • Young-Ran Yoon, M.D., Ph.D · Kyungpook National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2020-07-16
Completion
2020-07-16

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04375865 on ClinicalTrials.gov